Overview

Efficacy and Safety of Bivalirudin Versus Heparin During Coil Embolization in Patients With Ruptured Intracranial Aneurysms

Status:
Not yet recruiting

Trial end date:
2021-06-01

Target enrollment:

Participant gender:

Summary

This is a randomized, open label, multi-center, positive-controlled study, in which a total of 236 patients will be enrolled and randomly assigned to receive bivalirudin or heparin in a 1:1 ratio during coil embolization in patients with ruptured intracranial aneurysms. Procedure-related complication, mRS, Activated Clotting Time, ischemic and hemorrhagic complications, symptomatic and asymptomatic intracranial hemorrhage, death, Heparin Induced Thrombocytopenia will be evaluated during procedure, at 24hs, 7days and 30 days after.

Phase:

Phase 3

Details

Lead Sponsor:

Changhai Hospital

Collaborators:

Qilu Hospital of Shandong University
The First Affiliated Hospital of Zhengzhou University
The First People's Hospital of Changzhou
Wuhan University
Zhejiang University

Treatments:

Bivalirudin
Heparin